LYON, France–(BUSINESS WIRE)–Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announces today its financial calendar for 2018.
|March 19, 2018:||Publication of 2017 financial statements (Reference Document will be released during Q2 2018).|
|April 16, 2018:||Publication of revenue for Q1 2018.|
|May 17, 2018:||Annual shareholders’ meeting.|
|July 18, 2018:||Publication of mid-year financial statements as of June 30, 2018.|
|October 23, 2018:||Publication of revenue for Q3 2018.|
In addition to regular meetings with the financial community, investors are recommended to consult the regularly updated information available on the company’s website (www.adocia.com). All corporate information on the company – such as its financial statements, corporate presentation and its articles of association – is available on the company’s website, in the section « Financials-Investors Sections », « Regulated Information ».
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s portfolio of therapeutic proteins for the treatment of diabetes, featuring five clinical-stage products and four preclinical-stage products, is among the largest and most differentiated in the industry.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with synergistic prandial hormones (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide), and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.
Adocia aims to deliver “Innovative medicine for everyone, everywhere.”
To learn more about Adocia, please visit us at www.adocia.com
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the “Risk Factors” section of the Reference Document filed with the French Autorité des marchés financiers on April 11, 2017 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.
Chairman and CEO
Ph. : +33 4 72 610 610
Adocia Press Relations Europe
MC Services AG
Raimund Gabriel, Ph.: +49 89 210 228 0
Adocia Investor Relations USA
The Ruth Group
Tram Bui, Ph. : +1 646 536 7035
Automated Trading Systems to trade news? Hire A Programmer!
We will be updating our subscribers as soon as we receive more news. For the latest updates sign up above!